In this article
Molecular Discovery in Liver Regeneration and Repair
A new study conducted by a biochemist at the University of Illinois has determined how damaged liver cells repair and use signals to repair themselves back to the early stages of organ development. The results of this study were published in the journal Natural Structure and Molecular Biology.
Avinash Kalsotra, a professor of biochemistry who is responsible for the new research, said, “Healthy adult liver cells are dormant and seldom undergo cell division, but if the liver is damaged, the liver cells will re-enter the cell cycle and repair themselves. The liver It is a flexible organ that can repair 70% of the damage and function in a few weeks. “The human liver may be damaged for a long time by toxins such as alcohol or certain drugs, but it will continue to function and repair itself. The study looked at what happened to the damaged liver at the molecular level, allowing it to regenerate while functioning normally.
The Role of Gene Expression and RNA Splicing in Cell Recovery
The researchers used a mouse liver model that was severely damaged by the toxin to compare the injured adult liver cells with healthy cells in the developmental stage just after birth. The study found that the damaged cells could be restored to the gene expression state of the newborn after being partially re-edited. The messenger RNA fragments are rearranged and processed in the manner of neonatal development when hepatocytes are regenerated. This phenomenon is regulated by alternative splicing, where exons (expression regions of genes) are cut out from introns (insertion regions) and spliced ​​together in various combinations to guide the synthesis of different proteins from a single gene. These proteins have different cellular functions or characteristics.
The researchers found that liver cells use the specific RNA-binding protein ESRP2 to accurately classify splitable RNA. These RNAs can produce the proteins necessary for adult liver function. When damaged, liver cells reduce the amount of ESRP2 protein. This will reactivate fetal RNA splicing in the Hippo signaling pathway and indicate how to restore and repopulate the liver with new healthy cells. “
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.